HC Wainwright Reiterates “Buy” Rating for TAIWAN LIPOSOME/S (NASDAQ:TLC)

TAIWAN LIPOSOME/S (NASDAQ:TLC)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Thursday, AnalystRatings.com reports. They currently have a $11.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 103.79% from the stock’s previous close.

Several other equities analysts also recently commented on the stock. ValuEngine upgraded shares of TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating in a report on Tuesday, December 31st. Cantor Fitzgerald decreased their price objective on shares of TAIWAN LIPOSOME/S from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Zacks Investment Research downgraded shares of TAIWAN LIPOSOME/S from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $9.00.

NASDAQ:TLC opened at $5.40 on Thursday. TAIWAN LIPOSOME/S has a one year low of $4.61 and a one year high of $8.54. The company has a market cap of $200.24 million, a P/E ratio of -9.64 and a beta of 0.78. The firm’s fifty day moving average price is $5.38 and its two-hundred day moving average price is $5.23. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.01 and a quick ratio of 2.01.

An institutional investor recently raised its position in TAIWAN LIPOSOME/S stock. Millennium Management LLC lifted its holdings in TAIWAN LIPOSOME/S (NASDAQ:TLC) by 564.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 92,915 shares of the company’s stock after acquiring an additional 112,915 shares during the period. Millennium Management LLC owned approximately 0.29% of TAIWAN LIPOSOME/S worth $474,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 2.11% of the company’s stock.


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Article: What is a stock portfolio tracker?

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.